Expert consensus on the clinical rational use of hemocoagulase drugs
- VernacularTitle:血凝酶类药物临床合理应用专家共识
- Author:
Zinan ZHAO
1
;
Zaiwei SONG
2
;
Yudi ZHANG
3
;
Fei ZHAO
1
;
Xin HU
1
;
Pengfei JIN
1
;
Association GERIATRIC
1
;
Association PHARMACY
1
;
Association CLINICAL
1
Author Information
1. Dept. of Pharmacy，Beijing Hospital （National Center for Gerontology），National Clinical Research Center for Geriatric Diseases，Key Laboratory of Geriatric Medicine，National Health Commission，Institute of Geriatric Medicine，Chinese Academy of Medical Sciences，Beijing 100730，China
2. Dept. of Pharmacy，Peking University Third Hospital，Beijing 100191，China
3. Dept. of Obstetrics and Gynecology，Beijing Obstetrics and Gynecology Hospital，Capital Medical University，Beijing 100006，China
- Publication Type:Journal Article
- Keywords:
rational drug use;
standardized management;
expert consensus
- From:
China Pharmacy
2026;37(17):2213-2223
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To formulate Expert Consensus on the Clinical Rational Use of Hemocoagulase Drugs， thereby providing a decision-making basis for the rational clinical application and standardized management of hemocoagulase drugs （hereinafter referred to as “hemocoagulase”）.METHODS Led by Beijing Hospital （National Center for Gerontology）， in collaboration with 34 experts in clinical pharmacy， orthopedics， neurosurgery， emergency medicine， obstetrics and gynecology， gastroenterology， and other relevant fields， the consensus was developed through a systematic review of domestic and international research evidence and clinical practice experience pertaining to 10 clinical practice issues concerning hemocoagulase， followed by in-depth discussion.RESULTS A total of 24 recommendations were formulated， covering the following 10 aspects： the routes of administration and scope of application； dosage under different routes of administration； medication monitoring and management； adverse reaction management； medication monitoring and management in special populations； the combined use of hemocoagulase with common hemostatic drugs and/or hemostatic materials； the use of injectable hemocoagulase to reduce perioperative bleeding； the use of locally applied hemocoagulase to reduce perioperative bleeding； the application of hemocoagulase in reducing non-surgery-related bleeding； and the application of hemocoagulase in reducing trauma-related bleeding.CONCLUSIONS This consensus provides systematic， evidence-based guidance for the clinical application of hemocoagulase， facilitating the standardization of clinical practice， the optimization of dosing regimens， and the assurance of medication safety， thereby improving patient treatment outcomes.
